---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-004651"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2022-01-18T23:59:59+00:00"
generated_at: "2026-06-27T17:38:11.467114+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Immuneering appoints Diana F. Hausman, M.D. to Board of Directors

## Summary
- Dr. Hausman appointed Class I Director effective January 14, 2022; Board now has six members.
- She brings over 20 years of clinical drug development experience, including CMO roles at Zymeworks and Oncothyreon.
- Currently Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines (Nasdaq: BPMC).
- No committee assignment yet; will receive standard non-management director compensation.
- Her expertise in oncology and RAS mutant solid tumors supports lead candidate IMM-1-104 development.

## SEC filing metadata
- accession: 0001104659-22-004651
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2022-01-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000110465922004651/0001104659-22-004651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000110465922004651/tm223100d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-004651
- JSON: https://secwatch.observer/filing/0001104659-22-004651.json
- Plain text: https://secwatch.observer/filing/0001104659-22-004651.txt

## Key facts
- Executive change
  Diana F. Hausman, MD was appointed as Class I Director at Immuneering Corp.
  - Action: appointed
  - Role: Class I Director
  source text: On January 14, 2022, the Board of Directors of Immuneering Corporation (the “Company”) appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000110465922004651/0001104659-22-004651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.